Gallium68FAPIQualityChecker

Gallium-68 FAPI Quality Checker — ⁶⁸Ga-FAPI for PET imaging of tumor stroma

ℹ️  Utility checks quality of FAPI (Fibroblast Activation Protein Inhibitor) radiopharmaceutical:
    • Specific activity (≥50 GBq/μmol)
    • Radiochemical purity (≥95%)
    • Germanium-68 impurity (≤0.001%)
    • Free gallium-68 (≤5%)
    • pH, endotoxins, sterility, heavy metals, aluminium

⚠️  IMPORTANT: ⁶⁸Ga-FAPI is in clinical trials phase (2019-2024).
    Not approved by FDA/EMA as standard of care. Intended for:
    • Research use
    • Compassionate therapy
    • Clinical trials

Usage:
  Gallium68FAPIQualityChecker.exe                            → demo mode (console output)
  Gallium68FAPIQualityChecker.exe input.csv output.json      → evaluate your data

Input format:
BatchNumber,SpecificActivityGBqPerUmol,RadiochemicalPurityPercent,Germanium68ImpurityPercent,FreeGallium68Percent,pH,EndotoxinsEU,SterilityTest,HeavyMetalsPPM,AluminiumPPM,ResidualEthanolPPM,TumorType

Example (sterility: 0=sterile, 1=contaminated):
  GA68-FAPI-2026-001,60.0,97.5,0.0005,3.0,6.2,120.0,0,5,5.0,2000,Pancreatic

— WHY IS THIS NEEDED?
FAPI (Fibroblast Activation Protein Inhibitor) — promising ligand for imaging and therapy of solid tumors:
• Binds to FAP protein expressed by cancer-associated fibroblasts (CAFs) in tumor stroma
• FAP expression found in 90%+ solid tumors (pancreas, stomach, liver, colorectal cancer)
• Practically absent in healthy adult tissues (only in healing wounds, placenta)
• ⁶⁸Ga-FAPI PET shows superiority over FDG for:
  — Pancreatic ductal adenocarcinoma (2-3x higher SUVmax)
  — Primary liver tumors (better HCC visualization)
  — Gastric cancer (superior primary tumor detection)

⚠️  CRITICAL:
• Specific activity ≥50 GBq/μmol — critical for optimal tumor stroma uptake
• Germanium-68 impurity ≤0.001% — CRITICAL! Germanium-68 has 271-DAY half-life!
  Even 0.0011% creates chronic radiation burden without diagnostic benefit.
• Free gallium-68 ≤5% — UNBOUND gallium accumulates in bones, masking metastases
• Aluminium <10 ppm — concentrations ≥10 ppm cause bone uptake artifacts on PET
• pH 4.5–7.5 — critical for blood compatibility during IV administration
• Endotoxins ≤175 EU/vial — critical for IV administration!
• Sterility — MANDATORY for all parenteral forms!

Key features:
• Support for different tumor types with clinical evidence display
• Critical warnings: "CHRONIC RADIATION BURDEN!", "BONE MARROW UPTAKE!"
• Automatic verification against 2019-2024 research specifications
• Demo data for pancreatic cancer (most studied type)

Critical parameters:
• Specific activity: ≥50 GBq/μmol (same as ⁶⁸Ga-DOTATATE)
• Radiochemical purity: ≥95.0%
• Germanium-68 impurity: ≤0.001% (CRITICAL: 271-DAY HALF-LIFE!)
• Free gallium-68: ≤5.0% (bone metastasis masking)
• pH: 4.5–7.5 (blood compatibility)
• Endotoxins: ≤175 EU/vial (LAL test)
• Sterility: no microbial growth
• Heavy metals: ≤10 ppm
• Aluminium: <10 ppm (IMAGE ARTIFACTS!)
• Residual ethanol: ≤5000 ppm

⚠️  Product status (2024):
• Not approved by FDA/EMA as standard of care
• Used in Germany, China, Russia clinics for compassionate therapy
• 50+ clinical studies, 2000+ patients
• Approved for clinical use in China since 2022
• Key studies: Kratochwil et al. (J Nucl Med 2019), Giesel et al. (EJNMMI 2022)

💡 Usage tips:
1. For research use ensure protocol approved by ethics committee
2. Germanium-68 impurity >0.001% makes batch unsuitable even for research
3. Free gallium-68 >5% requires re-purification
4. Document all measurements for clinical trial reporting

⚠️  Limitations:
• Parameters based on current research and may be refined upon regulatory approval
• Utility does NOT replace official pharmacopoeial quality control
• Intended for research use and compassionate therapy
• Not a medical device

Data sources:
• Kratochwil C, et al. ⁶⁸Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer. J Nucl Med. 2019;60(6):801-805.
• Giesel FL, et al. ⁶⁸Ga-FAPI PET/CT for pancreatic carcinoma: first clinical experience. Eur J Nucl Med Mol Imaging. 2020;47(7):1777-1779.
• Lindner T, et al. Development of Quinoline-Based FAP-Targeted Radiotracers for PET Imaging and Radionuclide Therapy. J Nucl Med. 2021;62(1):112-118.
• Chinese FDA approval for ⁶⁸Ga-FAPI clinical use (2022)